Top

Clinical and Translational Oncology

Published in:

01-10-2013 | Research Article

Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma

Authors: S. Guan, B. Liu, C. Zhang, K.-H. Lee, S. Sun, J. Wei

Published in: Clinical and Translational Oncology | Issue 10/2013

Abstract

Background

The present study was undertaken to develop an in-house enzyme-linked immunosorbent assay (ELISA) using human leukocyte antigen class II restricted epitopes to test circulating autoantibodies to CD25 as a biomarker for esophageal cancer.

Methods

A total of 97 patients with esophageal squamous cell carcinoma (ESCC) and 226 healthy subjects were recruited for this study and their plasma samples were collected for antibody analysis with the ELISA approach.

Results

Mann–Whitney U test showed that the IgG anti-CD25 antibody level was significantly higher in the patient group than the control group (P < 0.001) while the IgA antibody level was not significantly different between these two groups (P = 0.361). Spearman correlation analysis failed to reveal a significant correlation between the levels of anti-CD25 IgG and IgA antibodies in either the patient group (r = −0.027, P = 0.797, n = 94) or the control group (r = 0.055, P = 0.429, n = 209). The sensitivity against >90 % specificity was 37.2 % for the IgG assay with an inter-assay deviation of 9.4 %, and 8.2 % for the IgA assay with an inter-assay deviation of 13.0 %. Based on a cut-off value determined by the 99th percentile of control IgG levels, the positive rate was 7.4 % in patients with ESCC, in which patients at stage I had the highest positivity (11.5 %) (χ ² = 11.10, P = 0.001, OR = 12.12, 95 % CI 1.93–75.94).

Conclusions

This work suggests that circulating IgG autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal cancer.

Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349:2241–2245PubMedCrossRef

Lam KY, Ma L (1997) Pathology of esophageal cancers: local experience and current insights. Chin Med J (Eng) 110:459–464

Polednak AP (2003) Trends in survival for both histologic types of esophageal cancer in US surveillance, epidemiology and end results areas. Int J Cancer 105:98–100PubMedCrossRef

Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston C, Sahin U, Barnes A, Robertson J (2007) Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 18:868–873PubMedCrossRef

Tan HT, Low J, Lim SG, Chung MC (2009) Serum autoantibodies as biomarkers for early cancer detection. FEBS J 276:6880–6904PubMedCrossRef

Ranju R, Arora S, Chattopadhyay TK, Shukla NK, Mathur M (2000) Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India. Int J Cancer 86:791–795

Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, Funami Y, Hayashi H, Gunji Y, Suzuki T, Kobayashi S, Ochiai T (2000) Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer 89:1677–1683PubMedCrossRef

Fujita Y, Nakanishi T, Hiramatsu M, Mabuchi H, Miyamoto Y, Miyamoto A, Shimizu A, Tanigawa N (2006) Proteomics based approach identifying autoantibody against Peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clin Cancer Res 12:6415–6420PubMedCrossRef

Fujita Y, Nakanishi T, Miyamoto Y, Hiramatsu M, Mabuchi H, Miyamoto A, Shimizu A, Takubo T, Tanigawa N (2008) Protemics based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma. Cancer Lett 263:280–290PubMedCrossRef

10.

Dong J, Zeng B-H, Xu L-H, Wang J-Y, Li M-Z, Zeng M-S, Liu W-L (2010) Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma. J Transl Med 8:81. doi:10.1186/1479-5876-8-81 PubMedCrossRef

11.

Zhou J-H, Zhang B, Kernstine KH, Zhong L (2011) Autoantibodies against MMP-7 as a novel diagnostic biomarker in esophageal squamous cell carcinoma. World J Gastroenterol 17:1373–1378PubMedCrossRef

12.

Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of selftolerance causes various autoimmune diseases. J Immunol 155:1151–1164PubMed

13.

Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4tCD25⁺ regulatory T cells. Nat Immunol 4:330–336PubMedCrossRef

14.

Serafini P, De Santo C, Marigo I, Cingarlini S, Dolcetti L, Gallina G, Zanovello P, Bronte V (2004) Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 53:64–72PubMedCrossRef

15.

Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM (2006) Chen SH (2006) Gr-1⁺CD115⁺ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66:1123–1131PubMedCrossRef

16.

Awasthi A, Carrier Y, Peron JP, Bettelli E, Kamanaka M, Flavell RA, Kuchroo VK, Oukka M, Weiner HL (2007) A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol 8:1380–1389PubMedCrossRef

17.

Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS, Vignali DA (2007) The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450:566–569PubMedCrossRef

18.

Li C-H, Kuo W-H, Chang W-C, Huang S-C, Chang K-J, Sheu B-C (2011) Activation of regulatory T cells instigates functional down-regulation of cytotoxic T lymphocytes in human breast cancer. Immunol Res 51:71–79PubMedCrossRef

19.

Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, Malchin-khuu E, Wersto RP, Biragyn A (2011) Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cell. Cancer Res 71:3505–3515PubMedCrossRef

20.

Wang YY, He XY, Cai YY, Wang ZJ, Lu SH (2011) The variation of CD4+CD25+ regulatory T cells in the periphery blood and tumor microenvironment of nonsmall cell lung cancer patients and the downregulation effects induced by CpG ODN. Target Oncol 6:147–154PubMedCrossRef

21.

Erfani N, Mehrabadi SM, Ghayumi MA, Haghshenas MR, Mojtahedi Z, Ghaderi A, Amani D (2012) Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC). Lung Cancer 77:306–311PubMedCrossRef

22.

Ye L, Li X, Sun S, Guan S, Wang M, Guan X, Lee K-H, Wei j, Liu B (2012) A study of circulating anti-CD25 antibodies in non-small cell lung cancer. Clin Transl Oncol (Epub ahead of print)

23.

Liu L, Liu N, Liu B, Yang Y, Zhang Q, Zhang W, Yu P, Jin Y, Guo J, Guan S, Sun S, Miao L, Wei J (2012) Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer? J Cancer Res Clin Oncol 138:1737–1742PubMedCrossRef

24.

Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T Cells and immune tolerance. Cell 133:775–787PubMedCrossRef

25.

Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, Peek LJ, Allen J, Thorpe AJ, Hamilton-Fairley G, Parsy-Kowalska CB, MacDonald IK, Jewell W, Maddison P, Robertson JF (2012) EarlyCDT^®-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol 33:1319–1326PubMedCrossRef

Title: Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma
Authors: S. Guan
B. Liu
C. Zhang
K.-H. Lee
S. Sun
J. Wei
Publication date: 01-10-2013
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 10/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-013-1007-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2013

Ependymoma in children: molecular considerations and therapeutic insights

Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response

Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences

Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer

Expression and prognostic role of c-Myb as a novel cell cycle protein in esophageal squamous cell carcinoma

Clinical research in individual information of celiac artery CT imaging and gastric cancer surgery

Keynote webinar | Spotlight on antibody–drug conjugates in cancer